Novartis (VTX:NOVN) has been given a CHF 92 target price by stock analysts at Morgan Stanley in a research note issued to investors on Thursday, January 25th. The brokerage currently has a “buy” rating on the stock. Morgan Stanley’s target price would indicate a potential upside of 16.63% from the company’s previous close.
NOVN has been the subject of several other research reports. UBS Group set a CHF 78 price objective on Novartis and gave the stock a “neutral” rating in a report on Monday, October 23rd. JPMorgan Chase & Co. set a CHF 84 price target on Novartis and gave the company a “neutral” rating in a report on Friday, December 29th. Barclays set a CHF 80 price target on Novartis and gave the company a “sell” rating in a report on Thursday, January 25th. Credit Suisse Group set a CHF 77 price target on Novartis and gave the company a “neutral” rating in a report on Wednesday, January 24th. Finally, Goldman Sachs Group set a CHF 80 price objective on Novartis and gave the stock a “neutral” rating in a research note on Tuesday, October 17th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and seven have assigned a buy rating to the stock. Novartis has a consensus rating of “Hold” and an average price target of CHF 88.19.
Shares of Novartis (VTX NOVN) traded up CHF 1.48 on Thursday, hitting CHF 78.88. The company had a trading volume of 6,040,000 shares, compared to its average volume of 5,480,000. Novartis has a one year low of CHF 72.45 and a one year high of CHF 88.30. The company has a market capitalization of $206,420.00 and a price-to-earnings ratio of 25.95.
ILLEGAL ACTIVITY NOTICE: This news story was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright law. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2018/02/12/novartis-novn-pt-set-at-chf-92-by-morgan-stanley.html.
Novartis Company Profile
Novan, Inc, a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris.
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.